Everolimus added to standard care for gallbladder cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding everolimus to the usual treatment helps people with advanced (stage III inoperable or stage IV) gallbladder cancer live longer and control the disease better. You may be eligible if you have not had prior treatment for the advanced cancer, and your blood tests and organ functions are in safe ranges.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have gallbladder cancer confirmed by biopsy (stage III that can’t be removed or stage IV spread).
- You have not been treated for metastatic (advanced) gallbladder cancer yet, or you finished adjuvant treatment with gemcitabine and/or capecitabine (with or without platinum) at least 6 months ago.
- Your blood counts are strong enough: neutrophils (ANC) ≥ 1,500 and platelets ≥ 100,000, and hemoglobin ≥ 8.0.
- Your liver, kidney, and clotting tests are within required limits (including bilirubin and liver enzymes not too high).
- You are able to care for yourself day-to-day (ECOG 0–2) and you can provide consent and return for follow-up visits.
- You can’t take certain medicines that interact with everolimus, and you must have no prior everolimus treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
This trial tests whether combining an immunotherapy drug (AK112) with chemotherapy can shrink advanced gallbladder cancer enough to make surgery possible. The goal is to give patients a chance at curative surgery who otherwise might not have one.
This Phase 3 study tests whether adding everolimus to chemotherapy (chosen by the treating team) can improve outcomes in advanced triple-negative breast cancer, specifically a subtype linked to PAM pathway changes. It may help patients who have not yet had treatment for advanced/metastatic disease.
This trial tests whether the drug everolimus can help prevent liver cancer from coming back after surgery. It is for people with high-risk liver cancer who have had their tumor completely removed.
This trial tests whether adding a targeted therapy (anlotinib) to standard chemo plus an immunotherapy (camrelizumab) is more effective than chemo plus immunotherapy alone for advanced gallbladder or bile duct cancers that cannot be removed by surgery.
This trial tests the combination of everolimus (a targeted pill) with a PD-1 immunotherapy drug for people with advanced colorectal cancer that has a specific gene change (PTEN mutation). The goal is to see if this two-drug approach works better than standard treatments for cancers that have stopped responding to chemotherapy.
Hear when a new Gallbladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.